Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. (Q47956183)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 November 2015

Language	Label	Description	Also known as
English	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.	scientific article published on 19 November 2015

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26608256

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26608256

steatohepatitis

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

non-alcoholic steatohepatitis

1 reference

based on heuristic

inferred from title

Guruprasad P. Aithal

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Matthew J Armstrong

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jonathan Hazlehurst

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jeremy W Tomlinson

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

2

object named as

Piers Gaunt

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

8

object named as

Kathy Guo

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Deborah Stocken

12

object named as

Deborah Stocken

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Diana Hull

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

LEAN trial team

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

George Abouda

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Mark A Aldersley

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Stephen C Gough

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Rachel M Brown

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Stefan G Hübscher

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

0 references

publication date

19 November 2015

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/26608256

number of pages

12

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

387

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

679-690

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

10019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26608256%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Extrahepatic complications of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacological agents for NASH.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Incretin mimetics as a novel therapeutic option for hepatic steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Endpoints and clinical trial design for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900803-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47956183&oldid=1988619169"